

Harmonizing Global Treatment Initiation

The Tale of Varied Color Starting Flags

Julio Montaner, MD

Professor of Medicine, and Head, Div. of AIDS, University of British Columbia
Director, BC-Centre for Excellence in HIV/AIDS at Providence Health Care
UNAIDS Special Advisor on HIV Therapeutics

IAPAC – Controlling the HIV Epidemic with Antiretrovirals Summit
Sept 18th 2014

a place of mind




BC Centre for Disease Control
AN AGENCY OF THE PROVINCIAL HEALTH SERVICES AUTHORITY



How you want to be treated.

Methods



ART initiation for asymptomatic PLHIV

published + reported

ART criteria	Countries	PLHIV (2012)	Countries
Irrespective of CD4 count	9	924,000 (3%)	Australia, Belgium , Brazil, British Columbia (Canada), France, Korea, the Netherlands, Panama , Spain, United States
Consider for CD4 >500	6	127,700 (0.3%)	Argentina, Austria, Germany, Guyana, Hong Kong, Italy
≤500	29	11,000,000 (31%)	Afghanistan , Angola , Algeria, Bangladesh , Belize , Bolivia, Cambodia , Chad , Ecuador, Ethiopia, Fiji , Gabon , Honduras, India , Kenya, Madagascar, Malawi, Morocco , Namibia, Nepal , Rwanda, Sri Lanka, Timor-Leste , Tunisia, Uganda, Venezuela, Yemen , Zambia, Zimbabwe
≤350 & consider for CD4 ≤ 500	3	775,000 (2%)	Costa Rica, Guinea, Mexico, Thailand , Uruguay, Europe

ART initiation for asymptomatic PLHIV

published + reported

ART criteria	Countries	PLHIV (2012)	Countries
≤350	59	16,977,000 (49%)	Armenia, Benin, Bhutan, Botswana, Britain, British Virgin Islands, Burkina Faso, Burundi, Canada, Cape Verde, Chile, China, Comoros, Congo, Democratic Republic of Congo, Djibouti, Egypt, El Salvador, Equatorial Guinea, Eritrea, Gambia, Ghana, Guatemala, Guinea-Bissau, Haiti, Indonesia, Jamaica, Kazakhstan, Kyrgyzstan, Lesotho, Malaysia, Mali, Mauritania, Mauritius, Moldova, Mozambique, Myanmar, Nicaragua, Niger, Nigeria, Papua New Guinea, Paraguay, Peru, Sao Tome, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Swaziland, Sweden, Switzerland, Tajikistan, Tanzania, Togo, Ukraine, Vietnam
≤300	1	34,700 (0.1%)	Uzbekistan
≤250 (consider for CD4 ≤ 350)	1	140,000 (0.4%)	Colombia
≤200 (consider for CD4 ≤ 350)	2	16,000 (0%)	Cuba, Russia
≤200	7	1,119,800 (3%)	Cameroon, Dominican Republic, Ivory Coast, Lao PDR, Liberia, Pakistan, Philippines

ART initiation for asymptomatic PLHIV


ART criteria	Countries	PLHIV (2012)
Irrespective of CD4 count	9	924,000 (3%)
Consider for CD4 >500	6	127,700 (0.3%)
≤500	29	11,000,000 (31%)
≤350 & consider for CD4 ≤ 500	3	775,000 (2%)
≤350	59	16,977,000 (49%)
≤300	1	34,700 (0.1%)
≤250 (consider for CD4 ≤ 350)	1	140,000 (0.4%)
≤200 (consider for CD4 ≤ 350)	2	16,000 (0%)
≤200	7	1,119,800 (3%)

47 Countries
36.3 % PLHIV


70 Countries
52.5% PLHIV

ART initiation for asymptomatic PLHIV


(published policy and reported)




Before 2010



Late 2013



Early 2013



ART eligibility for children <5 years

WHO 2013 Guidelines: ART irrespective of CD4 count

ART INITIATION CRITERIA	NUMBER	CHILDREN WITH HIV	COUNTRIES
Irrespective of CD4 count for children <5	9	1,342,000 (42%)	Honduras, Kenya, Malawi, Namibia, Rwanda, South Africa, Uganda, Zambia, Zimbabwe
Irrespective of CD4 count for children <2	24	1,203,400 (37.6%)	Algeria, Argentina, Bangladesh, Benin, Botswana, Burundi, Cambodia, Democratic Republic of Congo, Ghana, Guyana, India, Kazakhstan, Lesotho, Morocco, Mozambique, Myanmar, Nepal, Nigeria, Panama, Papua New Guinea, Swaziland, Tanzania, Venezuela, Viet Nam
Irrespective of CD4 count for children <1	14	287,100 (9%)	Angola, Brazil, Burkina Faso, Costa Rica, Ethiopia, Guatemala, Hong Kong, Madagascar, Mexico, Sri Lanka, Sweden, Thailand, Tunisia, United States
Conditional (Children must satisfy clinical prerequisites)	19	208,100 (6.5%)	Afghanistan, Bhutan, Cameroon, Cape Verde, Chile, Comoros, Djibouti, Dominican Republic, El Salvador, Guinea, Haiti, Ivory Coast, Lao PDR, Liberia, Malaysia, Mauritania, Peru, Sierra Leone, Ukraine

Source: published policy

ART eligibility for PLHIV with TB (published policy)

2013 WHO Recommendation : Irrespective of CD4 count

ART INITIATION CRITERIA	COUNTRIES	COUNTRIES
Irrespective of CD4 count	58	Argentina, Algeria, Australia, Bangladesh, Belize, Benin, Bolivia, Botswana, Brazil, Britain, Burundi, Cambodia, Chile, China, Costa Rica, Democratic Republic of Congo, Ecuador, Ethiopia, France, Ghana, Haiti, Honduras, Hong Kong, India, Indonesia, Italy, Jamaica, Kenya, Korea, Lesotho, Madagascar, Malawi, Mexico, Morocco, Mozambique, Namibia, Nepal, Netherlands, Nigeria, Panama, Papua New Guinea, Peru, Rwanda, South Africa, Spain, Sri Lanka, Swaziland, Switzerland, Tanzania, Tunisia, Uganda, United States, Ukraine, Uruguay, Venezuela, Viet Nam, Zambia, Zimbabwe
≤500	1	Myanmar*
≤350	16	Afghanistan, Angola, Bhutan, Burkina Faso, Cameroon, Cuba, Djibouti, Guyana, Lao PDR, Liberia, Malaysia**, Pakistan, Paraguay, Philippines, Sierra Leone, Thailand
≤200	1	Comoros
No mention	18	Austria, Canada, Cape Verde, Colombia, Cote d'Ivoire, Germany, Guinea, Dominican Republic, El Salvador, Guatemala, Kazakhstan, Mauritania, Moldova, Nicaragua, Niger, Russia, Senegal, Sweden

*ART is recommended irrespective of CD4 count for extrapulmonary and disseminated TB patients or MDR TB

** ART is recommended at CD4 > 350 cells/mm³ if other WHO stage III or IV illnesses are present

ART eligibility for pregnant women (published policy)

2013 WHO Recommendation : Irrespective of CD4 count

ART INITIATION CRITERIA	NO. OF COUNTRIES	COUNTRIES
Option B+	42	Algeria, Argentina, Australia, Austria, Benin, Bolivia, Brazil, Cambodia, Costa Rica, Ecuador, Ethiopia, France, Germany, Guatemala, Honduras, India, Indonesia, Italy, Kenya, Korea, Madagascar, Malawi, Mexico, Morocco, Namibia, Netherlands, Nicaragua, Papua New Guinea, Paraguay, Peru, Rwanda, Spain, Sri Lanka, Switzerland, Uganda, United States, Uruguay, Venezuela, Tanzania, Tunisia, Zambia, Zimbabwe
≤500 & consider for ≥500	1	Hong Kong (China)
≤350	31	Angola, Afghanistan, Bangladesh, Belize, Botswana, Britain, Burkina Faso, Burundi, Chile, China, DRC, Djibouti, El Salvador, Ghana, Guinea, Guyana, Haiti, Jamaica, Lesotho, Liberia, Mozambique, Myanmar, Nepal, Niger, Nigeria, Panama, South Africa, Swaziland, Sweden, Thailand, Viet Nam
≤200 (consider for ≤350)	1	Cape Verde
≤250	1	Colombia
≤200	11	Bhutan, Cameroon, Comoros, Cuba, Ivory Coast, Lao PDR, Mauritania, Pakistan, Philippines, Senegal, Sierra Leone
No mention	7	Canada, Dominican Republic, Kazakhstan, Malaysia, Moldova, Russia, Ukraine

ART initiation for serodiscordant couples (published policy)

2013 WHO Recommendation : Irrespective of CD4 count

ART INITIATION CRITERIA	NO. OF COUNTRIES	COUNTRIES
Irrespective of CD4 count	32	Algeria, Argentina, Australia, Austria, Benin, Bolivia, Brazil, Canada, China, Costa, Rica, Ecuador, France, Germany, Honduras, Hong Kong, Indonesia, Italy, Kenya, Korea, Madagascar, Namibia, Netherlands, Rwanda, Spain, Sri Lanka, United States, Uganda, Uruguay, Tunisia, Venezuela, Zambia, Zimbabwe

ART eligibility for PLHIV with HBV Liver Disease


(published policy)

2013 WHO Recommendation : Irrespective of CD4 count




ART INITIATION CRITERIA	NO. OF COUNTRIES	COUNTRIES
Irrespective of CD4 count	52	Algeria, Angola, Argentina, Australia, Austria, Bangladesh, Belize, Bolivia, Brazil, Burundi, Costa Rica, Cuba, Ecuador, France, Germany, Guatemala, Haiti, Honduras, Hong Kong, India, Indonesia, Italy, Jamaica, Kenya, Lesotho, Madagascar, Malawi, Malaysia, Mexico, Morocco, Myanmar, Namibia, Nepal, Netherlands, Nicaragua, Nigeria, Papua New Guinea, Paraguay, Peru, Rwanda, South Korea, Spain, Sri Lanka, Swaziland, Thailand, Tunisia, Uganda, United States, Uruguay, Venezuela, Zambia, Zimbabwe
<500	2	Britain, Switzerland
Same as eligibility	40	Afghanistan, Benin, Bhutan, Botswana, Burkina Faso, Cambodia, Cameroon, Canada, Cape Verde, Chile, China, Colombia, Comoros, Cote d'Ivoire, Democratic Republic of Congo, Djibouti, Dominican Republic, El Salvador, Ethiopia, Ghana, Guinea, Guyana, Kazakhstan, Lao PDR, Liberia, Mauritania, Moldova, Mozambique, Niger, Pakistan, Panama, Philippines, Russia, Senegal, Sierra Leone, South Africa, Sweden, Tanzania, Ukraine, Viet Nam

TOTAL ANTIRETROVIRAL TREATMENT COVERAGE BY REGION IN 2013


- Total ART coverage
- Gap




ANTIRETROVIRAL TREATMENT COVERAGE VARIES WITHIN AFRICA



Source: UNAIDS estimates 2013.




Ambitious, but achievable, new target



by 2020

The objective

“Maximize the effectiveness of existing tools by 2020, to virtually eliminate progression to AIDS, premature death and HIV transmission, and thereby transform the HIV/AIDS pandemic into a low level sporadic endemic by 2030.”



Joep Lange: Pioneering HIV/AIDS researcher. Born Sept 25, 1954, in Nieuwenhagen, the Netherlands; assassinated in the MH17 bombing, Ukraine on July 17, 2014, at the age of 59.

